|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 48/00 | |
| C12N 15/64 | |||
| C12N 5/10 |
| (11) | Number of the document | 3110454 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15752803.5 |
| Date of filing the European patent application | 2015-02-24 | |
| (97) | Date of publication of the European application | 2017-01-04 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/017302 |
| Date | 2015-02-24 |
| (87) | Number | WO 2015/127439 |
| Date | 2015-08-27 |
| (30) | Number | Date | Country code |
| 201461943865 P | 2014-02-24 | US |
| (72) |
HOLMES, Michael C., US
WECHSLER, Thomas, US
|
| (73) |
Sangamo Therapeutics, Inc.,
501 Canal Blvd. Suite A100, Richmond, CA 94804,
US
|
| (54) | METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED TARGETED INTEGRATION |
| METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED TARGETED INTEGRATION |